Grifols SA - Company Profile
Powered by 
All the data and insights you need on Grifols SA in one report.
$295
- Save hours of research time and resources with
our up-to-date Grifols SA Strategy Report
- Understand Grifols SA position in the market,
performance and strategic initiatives.
- Gain competitive edge and increase your
chances of success
Get in touch about GlobalData Company reports
Contact the team or request a demo to find out how our data can drive your business forward
Grifols SA (Grifols) develops, produces, and markets plasma-derived medicines and transfusion medicines. The company is focused on research, development, manufacturing and marketing of plasma-derived therapies, hospital pharmacy products and diagnostic technology for clinical use. It produces plasma derived protein therapies for patients suffering with rare, chronic and life-threatening infections. The company's major products include essential plasma-derived medicines for treating conditions across various therapeutic areas such as neurology, immunology, hepatology, intensive care, pulmonology, hematology, and infectious diseases. Grifols provides transfusion medicine, hemostasis and immunoassay solutions for blood banks, clinical laboratories and transfusion centers. The company offers its products to hospitals, pharmacies and healthcare professionals. It offers products in the US, Canada, Europe, and Rest of the world. Grifols is headquartered in Barcelona, Spain.
Headquarters
Spain
Address
Jesus Y Maria, 6, Barcelona, Barcelona , 08022
Website
www.grifols.com
Telephone
34 935 710000
No of Employees
23,737
Industry
Pharmaceuticals and Healthcare
Ticker Symbol & Exchange
GRF (MCE)
Revenue (2022)
$7.1B
8.7%
(2022 vs 2021)
EPS
XYZ
Net Income (2022)
XYZ
-71.5%
(2022 vs 2021)
Market Cap*
$6.2B
Net Profit Margin (2022)
XYZ
-73.8%
(2022 vs 2021)
* As of and is in US$
Grifols SA premium industry data and analytics
Products and Services
| Products | Services | Brands |
|---|---|---|
| Bioscience: | Testing Services | Albutein |
| Plasma Derivative Products | Plasma Testing | Alphanate |
| Diagnostic: | Clinical Diagnostics | Anbinex |
| XYZ | XYZ | XYZ |
| XYZ | XYZ | XYZ |
| XYZ | XYZ | XYZ |
History
History section provides information on new products, mergers, acquisitions, expansions, approvals, and many more key events.
| Year | Event | Description |
|---|---|---|
| 2024 | New Products/Services | In April, the company launched Erytra Eflexis in China. |
| 2024 | New Products/Services | In February, the company launched 4- and 5-gram vials of PROLASTIN. |
| 2023 | New Product Approvals | In December, the company received FDA clearance for an Investigational New Drug (IND) of Oncology Drug Candidate, GIGA-564, for the treatment of solid tumors. |
Competitor Comparison
| Key Parameters | Grifols SA | Sanofi | Takeda Pharmaceutical Co Ltd | Vertex Pharmaceuticals Inc | CSL Behring GmbH |
|---|---|---|---|---|---|
| Headquarters | Spain | France | Japan | United States of America | Germany |
| City | Barcelona | Paris | Chuo-Ku | Boston | Marburg |
| State/Province | Barcelona | Ile-de-France | Tokyo | Massachusetts | Hessen |
| No. of Employees | 23,737 | 87,994 | 49,095 | 5,400 | 3,236 |
| Entity Type | Public | Public | Public | Public | Private |
Key Financial Charts
Sales Growth
Net Income Growth
Executives
| Name | Position | Board | Since | Age |
|---|---|---|---|---|
| Thomas H. Glanzmann | Chairman | Executive Board | 2023 | 65 |
| Raimon Grifols Roura | Chief Corporate Officer; Vice Chairman | Executive Board | 2023 | 60 |
| Nacho Abia | Chief Executive Officer; Director | Executive Board | 2024 | 55 |
| Victor Grifols Deu | Chief Operating Officer; Director | Executive Board | 2023 | 47 |
| Alfredo Arroyo Guerra | Chief Financial Officer | Senior Management | 2013 | 67 |
| Non Dignissim Eros | Proin vel | Convallis | 2024 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2024 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2024 | XY |
Still looking?
Have you found what you were looking for? From start-ups to market leaders, uncover what they do and how they do it.
Explorer
Access more premium companies when you subscribe to Explorer